September 20, 2017 12:46 AM ET

Healthcare Equipment and Supplies

Company Overview of Biosensors International Group, Ltd.

Company Overview

Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The Interventional Cardiology segment supplies proprietary drug-eluting stents, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMimics 3D, BioMatrix Flex, BioMatrix Flex BTK, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno,...

36 Jalan Tukang

Singapore,  619266

Singapore

Founded in 1990

Phone:

65 6213 5777

Fax:

65 6213 5737

Key Executives for Biosensors International Group, Ltd.

Chief Executive Officer and Executive Director
Age: 56
Founder and Executive Chairman
Age: 66
Chief Financial Officer and Company Secretary
Age: 58
Chief Executive Officer of JW Medical Systems Limited
Age: 67
President of Spectrum Dynamics Medical Ltd
Compensation as of Fiscal Year 2017.

Biosensors International Group, Ltd. Key Developments

Biosensors International Group To Be Deleted From Other OTC

Biosensors International Group Ltd ordinary shares (Bermuda) USD will be deleted from Other OTC, effective April 11, 2017. The deletion was due to inactive security.

Biosensors International Group, Ltd. Announces Enrollment of First Patient in New US Pivotal BioFreedom Trial

Biosensors International Group, Ltd. announced the enrollment of the first patient in LEADERS FREE II, its new BioFreedom Pivotal Study, conducted under an Investigational Device Exemption (IDE), which will include sites in the United States, Canada, Denmark, France Germany, Italy, and the United Kingdom.  The BioFreedom drug-coated stent (DCS) has been implanted to date in over 150,000 patients in more than 40 countries outside the United States. The initiation of LEADERS FREE II marks a key milestone on the path towards obtaining FDA approval for the BioFreedom DCS. Similar to LEADERS FREE, the therapeutic focus of this new US pivotal IDE trial is on patients at high bleeding risk (HBR) who receive an ultra-short dual anti-platelet drug regimen of only 1 month.

Biosensors International Group, Ltd.(SGX:B20) dropped from S&P Global BMI Index

Biosensors International Group, Ltd.(SGX:B20) dropped from S&P Global BMI Index

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 17, 2016
Good Parents Inc.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Biosensors International Group, Ltd., please visit www.biosensors.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.